As of March 23, 2026, Xeris Biopharma Holdings's top three insider holders are Paul R Edick (See Remarks, 3.79Mn shares), John Patrick Jr Shannon (See Remarks, 2.94Mn shares), Kevin Mcculloch (See Remarks, 1.73Mn shares).
| Holder | Position | Shares (Direct) | Shares (Indirect) | Report Date |
|---|---|---|---|---|
| Paul R Edick | See Remarks | 3,788,064 | 0 | 31 Jan, 2024 |
| John Patrick Jr Shannon | See Remarks | 2,935,578 | 0 | 02 Feb, 2026 |
| Kevin Mcculloch | See Remarks | 1,777,725 | 0 | 16 Mar, 2026 |
| Kevin Mcculloch | See Remarks | 1,727,827 | 0 | 02 Feb, 2026 |
| Steven Pieper | See Remarks | 1,408,940 | 0 | 05 Mar, 2026 |
| Beth Hecht | See Remarks | 1,226,507 | 0 | 04 Mar, 2026 |
| Steven Prestrelski | Chief Scientific Officer | 719,780 | 0 | 01 Feb, 2023 |
| John Johnson | 698,083 | 0 | 19 Dec, 2025 | |
| Anh Tu Nguyen | See Remarks | 395,023 | 0 | 25 Feb, 2026 |
| Kenneth Erland Johnson | See Remarks | 320,446 | 0 | 03 Feb, 2025 |
| Jeffrey W Sherman | 219,188 | 0 | 29 Aug, 2025 | |
| Garheng Kong | 214,144 | 0 | 04 Jun, 2025 | |
| Barbara-Jean Anne Bormann-Kennedy | 142,500 | 0 | 15 Dec, 2025 | |
| Marla Persky | 142,000 | 0 | 12 Sep, 2025 | |
| Ricki Louise Fairley | 135,000 | 0 | 05 Jun, 2024 | |
| Dawn Halkuff | 115,000 | 0 | 13 Aug, 2025 | |
| John P. Schmid | 113,159 | 0 | 05 Jun, 2024 | |
| James Aloysius Brady | 100,000 | 0 | 28 Mar, 2025 | |
| Paul R Edick | See Remarks | 0 | 33,430 | 16 Nov, 2021 |
| John P. Schmid | 0 | 25,200 | 13 Aug, 2024 | |
| Marla Persky | 0 | 6,370 | 15 Nov, 2023 | |
| Dawn Halkuff | 0 | 5,410 | 21 Nov, 2023 | |
| Jeffrey W Sherman | 0 | 5,400 | 29 Nov, 2023 |
* Please note that the shares above only reflect shares from the fund portfolio and the institutional portfolio. Shares from the personal portfolio are excluded from this Institutional Ownership Page. See these insiders' latest transactions here on Insider Page.
| Transaction Date | Insider Name | Security Class | Transaction Type | Shares Traded | Price | Shares Remaining | Ownership | Code |
|---|---|---|---|---|---|---|---|---|
| 12 Mar, 2026 | Kevin Mcculloch | Common Stock | A | 48,894 | $4.09 | 1,777,721 | D | M |
| 12 Mar, 2026 | Kevin Mcculloch | Common Stock | A | 4 | $3.94 | 1,777,725 | D | M |
| 12 Mar, 2026 | Kevin Mcculloch | Stock Option (Right to Buy) | D | 48,894 | $4.09 | 43,773 | D | M |
| 12 Mar, 2026 | Kevin Mcculloch | Stock Option (Right to Buy) | D | 4 | $3.94 | 79,996 | D | M |
| 05 Mar, 2026 | Steven Pieper | Common Stock | A | 27,891 | $4.09 | 1,394,904 | D | M |
| 05 Mar, 2026 | Steven Pieper | Common Stock | A | 14,036 | $5.93 | 1,408,940 | D | M |
| 05 Mar, 2026 | Steven Pieper | Stock Option (Right to Buy) | D | 27,891 | $0.00 | 0 | D | M |
| 05 Mar, 2026 | Steven Pieper | Stock Option (Right to Buy) | D | 14,036 | $0.00 | 0 | D | M |
| 02 Mar, 2026 | Beth Hecht | Common Stock | D | 16,567 | $6.24 | 1,226,607 | D | S |
| 02 Mar, 2026 | Beth Hecht | Common Stock | D | 100 | $7.06 | 1,226,507 | D | S |
| 24 Feb, 2026 | Anh Tu Nguyen | Common Stock | D | 29,300 | $6.88 | 395,023 | D | F |
| 30 Jan, 2026 | Anh Tu Nguyen | Common Stock | A | 121,293 | $0.00 | 424,323 | D | A |
| 30 Jan, 2026 | John Patrick Jr Shannon | Common Stock | A | 478,436 | $0.00 | 3,276,083 | D | A |
| 30 Jan, 2026 | Kevin Mcculloch | Common Stock | A | 168,463 | $0.00 | 1,853,889 | D | A |
| 30 Jan, 2026 | Beth Hecht | Common Stock | A | 121,293 | $0.00 | 1,429,396 | D | A |
| 30 Jan, 2026 | Steven Pieper | Common Stock | A | 154,986 | $0.00 | 1,572,547 | D | A |
| 30 Jan, 2026 | Kevin Mcculloch | Common Stock | A | 168,463 | $0.00 | 1,853,889 | D | A |
| 31 Jan, 2026 | John Patrick Jr Shannon | Common Stock | D | 118,134 | $7.36 | 3,157,949 | D | F |
| 31 Jan, 2026 | Steven Pieper | Common Stock | D | 111,765 | $7.36 | 1,460,782 | D | F |
| 31 Jan, 2026 | Kevin Mcculloch | Common Stock | D | 68,454 | $7.36 | 1,785,435 | D | F |